Date | Title | Description | |
---|---|---|---|
08 May 2024 | On P&L | The Company releases the first three months 2024 financial results presentation | Download |
25 Apr 2024 | On business and financial situation | ROVI announces agreement to manufacture pre-filled syringes | Download |
27 Feb 2024 | On P&L | The Company releases the full year 2023 financial results presentation. | Download |
27 Feb 2024 | About Corporate Governance | The Company informs about the agreements adopted by the Board of Directors | Download |
27 Feb 2024 | On P&L | The Company releases the press release related to the full year 2023 financial results. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
28 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 23 February 2022 and 25 February 2022 | Download |
23 Feb 2022 | Annual Report regarding remuneration of the members of the Board of Directors | ROVI releases the 2021 annual report regarding remuneration of the members of the Board of Directors | Download |
23 Feb 2022 | Annual Corporate Governance Report | ROVI releases the 2021 Annual Corporate Governance Report | Download |
21 Feb 2022 | Share buy-back , stabilisation and treasury stock programme | Share Buyback Program: transactions conducted between 14 February 2022 and 21 February 2022 | Download |
15 Feb 2022 | On business and financial situation | ROVI has announced that the European Commission has authorised the marketing of Okedi® for the treatment of schizophrenia in adults for whom tolerability and effectiveness has been established with oral risperidone. | Download |
Pages
Date | Title | Description | |
---|---|---|---|
08 Nov 2012 | Composición Consejo de Administración | Download | |
18 Sep 2012 | Otros sobre negocio y situación financiera | Download | |
26 Jul 2012 | Información sobre resultados (2) | Download | |
26 Jul 2012 | Información sobre resultados | Download | |
26 Jul 2012 | Información financiera intermedia | Download |